Skip to content
All resources

Copper peptides

Copper Peptides vs Matrixyl: What the Cosmetic Science Measured

IM

By

· 8 min read

A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.

On this page · 6 sections
  1. What are GHK-Cu and Matrixyl?
  2. Side by side
  3. What did the cell and skin-penetration studies show?
  4. What did the human cosmetic studies measure?
  5. Where is the line between a cosmetic claim and a drug claim?
  6. Frequently asked questions

GHK-Cu and Matrixyl are both short peptides used in skin-care formulations, and both trace back to fibroblast experiments in which a collagen-related sequence raised collagen production in culture. GHK-Cu is a tripeptide that binds copper. Matrixyl is the trade name for palmitoyl pentapeptide-4, a five-residue procollagen fragment (KTTKS) with a fatty-acid chain attached. Matrixyl has at least one sizeable placebo-controlled cosmetic trial; GHK-Cu has very few. No study has compared the two directly.

Two unlabelled glass dropper bottles beside a petri dish and a pipette
Illustration: cosmetic peptides are studied as formulations, not just molecules.

What are GHK-Cu and Matrixyl?

GHK-Cu is glycyl-L-histidyl-L-lysine bound to a copper(II) ion. The tripeptide was isolated from human plasma, and it has a strong affinity for copper. In the experiment the cosmetic field grew from, Maquart, Pickart and colleagues added the copper complex to cultured fibroblasts and found that collagen synthesis rose, starting at picomolar concentrations and peaking at nanomolar ones, without any change in cell number. They noted that the GHK sequence occurs within the alpha-2 chain of type I collagen and proposed that it might be released at a wound (PMID 3169264). The GHK-Cu wound repair article covers that origin in detail.

Matrixyl is the trade name of palmitoyl pentapeptide-4, also written pal-KTTKS: the sequence Lys-Thr-Thr-Lys-Ser with a palmitoyl group on the N-terminus. Its starting point was a 1993 paper by Katayama and colleagues, who dissected a fragment of the C-terminal propeptide of type I procollagen and found that KTTKS, residues 212 to 216, was the minimum sequence needed to stimulate collagen and fibronectin production in a range of mesenchymal cells (PMID 8486721). The palmitoyl chain was added later to change how the peptide behaves in skin.

Reviews of cosmetic peptides sort them into signal peptides, enzyme-inhibitor peptides, neurotransmitter-inhibitor peptides and carrier peptides (Gorouhi and Maibach, PMID 19570099). KTTKS, a matrix fragment proposed to signal fibroblasts, is the archetypal signal peptide; GHK's defining chemistry is that it carries copper.

Side by side

GHK-Cu (copper peptide)Matrixyl (palmitoyl pentapeptide-4)
IdentityGly-His-Lys complexed with copper(II)Palmitoyl-Lys-Thr-Thr-Lys-Ser (pal-KTTKS)
ClassCopper-binding tripeptide; found in human plasmaLipidated signal peptide derived from type I procollagen
Proposed mechanismStimulates collagen synthesis in fibroblast culture; copper deliveryStimulates collagen and fibronectin production in fibroblast culture
Evidence stageCell culture and animal wound models; very few controlled human skin studiesCell culture; skin-penetration studies; a few placebo-controlled cosmetic trials
Regulatory positionCosmetic ingredient; not an approved drugCosmetic ingredient; not an approved drug
What was measured in peopleErythema, wrinkle grading and satisfaction after laser resurfacingWrinkle and fine-line image analysis, expert grading, self-assessment

What did the cell and skin-penetration studies show?

Both founding results are cell-culture findings. A fibroblast making more collagen in a dish shows that a pathway responds. It does not show that the peptide reaches the dermis from a cream, or that the skin's appearance changes.

Penetration is the first barrier, and it has been measured more carefully for KTTKS. Choi and colleagues tested KTTKS and pal-KTTKS on hairless mouse skin. Both were broken down quickly by skin enzymes, with the palmitoylated form more stable. Neither crossed full-thickness skin into the receptor fluid. Plain KTTKS was not found in any skin layer, while pal-KTTKS was found in the stratum corneum, epidermis and dermis, in decreasing amounts (PMID 25143811). That supports the rationale for the palmitoyl chain, in mouse skin, and shows that only a small fraction reached the dermis.

For GHK-Cu, a 2024 review of the anti-wrinkle evidence concluded that cellular studies support its activity, that metal complexation and lipidation improve its permeability, and that there is "a surprising absence of clinical studies" of GHK-Cu and its palmitoylated form despite their wide use in products (Mortazavi and colleagues, PMID 39963574). The GHK-Cu photoageing article notes how much of the broader GHK literature is reviewed by the people who identified the peptide.

What did the human cosmetic studies measure?

Matrixyl. The most cited trial is Robinson and colleagues, from Procter & Gamble. 93 Caucasian women aged 35 to 55 used a moisturiser on one side of the face and the same moisturiser with pal-KTTKS on the other, for 12 weeks, in a double-blind, randomised, split-face design. The pal-KTTKS side showed significant improvement against the control side for wrinkles and fine lines by quantitative image analysis and by expert graders, and the product was well tolerated (PMID 18492182). That is a reasonable design for a cosmetic claim. It was run by a manufacturer, measured appearance by image analysis, and enrolled one demographic.

A smaller trial in Indonesia randomised 21 women with crow's feet to an acetyl hexapeptide-3 cream, a palmitoyl pentapeptide-4 cream or placebo for eight weeks. The authors reported better results with the pentapeptide and called the work an initial study needing more participants and a longer duration (Aruan and colleagues, PMID 36909866).

GHK-Cu. The controlled human data are thinner. Miller and colleagues randomised patients having carbon dioxide laser resurfacing around the mouth to skin-care regimens with or without GHK-Cu; 13 completed. Blinded evaluators and computer analysis found no significant difference in how quickly redness resolved, and no objective difference in wrinkles or overall skin quality at 12 weeks. Patients using the GHK-Cu products reported higher satisfaction (PMID 16847171).

So the comparison is uneven in an unexpected direction. GHK-Cu is the more famous molecule with the larger mechanistic literature; Matrixyl has the more directly relevant cosmetic trial evidence. Neither literature includes a head-to-head trial, and neither is independent of commercial interest. How to weigh small, sponsor-run studies is covered in the study design guide.

Where is the line between a cosmetic claim and a drug claim?

In Canada, the line is drawn by what a product is represented to do, not only by what is in it. Health Canada's guidance on the cosmetic-drug interface describes cosmetics as products for cleaning, improving or altering the complexion, skin, hair or teeth, expected to act superficially with at most a negligible, local and transient organic effect. A product represented as restoring, correcting or modifying organic functions, or as delivering benefits comparable to cosmetic surgery, points towards a therapeutic product.

That is why careful cosmetic copy speaks of the appearance of fine lines, not of rebuilding collagen. The fibroblast data that make both peptides interesting describe a change in a biological function, which is exactly the language that would move a product across the line. Wound healing, where much of the GHK-Cu animal literature sits, is a therapeutic question by definition.

Formulation adds its own variables. Copper is redox-active and can interact with other ingredients, and pH and concentration affect both stability and irritation, as why GHK-Cu can sting explains. A 2026 framework for the safety assessment of cosmetic peptides, written by Procter & Gamble scientists, reported that palmitoyl pentapeptide-4 shares sequence homology with skin matrix proteins without the toxin or allergen flags its bioinformatic screens were designed to catch (Bjerke and colleagues, PMID 41953401).

Supplied here for laboratory use: GHK-Cu. The laboratory's certificate for each lot is linked from its product page. For laboratory research use only.

Laboratory GHK-Cu is a research reagent, not a cosmetic, and NovaEvum does not sell Matrixyl. For how GHK-Cu compares with a quite different peptide, see GHK-Cu vs BPC-157. Nothing here is medical, dosing, or therapeutic guidance.

Frequently asked questions

Is Matrixyl a copper peptide? No. Matrixyl is palmitoyl pentapeptide-4, the five-residue sequence KTTKS from type I procollagen with a palmitoyl chain attached. It contains no copper. GHK-Cu is a different, three-residue peptide bound to a copper ion. Both are used in skin-care products and both were first studied for effects on collagen in fibroblast culture.

Which has better evidence in people? For cosmetic endpoints, Matrixyl. A 12-week, double-blind, split-face trial in 93 women reported less visible wrinkling on the treated side by image analysis. GHK-Cu's controlled human evidence is very limited: one small laser-resurfacing study found no objective difference from control. A 2024 review called the absence of GHK-Cu clinical studies surprising.

Do these peptides reach the dermis? Only partly, on the evidence available. In hairless mouse skin, plain KTTKS was not detected in any layer, while palmitoylated KTTKS reached the dermis in small amounts and neither crossed the full thickness. Reviews of GHK-Cu report that copper binding and lipidation increase permeability but describe skin penetration as a limiting problem.

Has anyone compared GHK-Cu and Matrixyl directly? No published study has compared them head to head in people. Some commercial products combine several peptides, which makes it impossible to attribute any result to one ingredient. Comparisons between the two rest on separate studies with different designs, populations and measurements.

Selected Research References

  1. Maquart FX, Pickart L, Laurent M, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters. 1988;238(2):343-346. pubmed.ncbi.nlm.nih.gov/3169264
  2. Katayama K, Armendariz-Borunda J, Raghow R, et al. A pentapeptide from type I procollagen promotes extracellular matrix production. Journal of Biological Chemistry. 1993;268(14):9941-9944. pubmed.ncbi.nlm.nih.gov/8486721
  3. Robinson LR, Fitzgerald NC, Doughty DG, et al. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. International Journal of Cosmetic Science. 2005;27(3):155-160. pubmed.ncbi.nlm.nih.gov/18492182
  4. Choi YL, Park EJ, Kim E, et al. Dermal stability and in vitro skin permeation of collagen pentapeptides (KTTKS and palmitoyl-KTTKS). Biomolecules & Therapeutics. 2014;22(4):321-327. pubmed.ncbi.nlm.nih.gov/25143811
  5. Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Archives of Facial Plastic Surgery. 2006;8(4):252-259. pubmed.ncbi.nlm.nih.gov/16847171
  6. Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. Topically applied GHK as an anti-wrinkle peptide: advantages, problems and prospective. BioImpacts. 2024;15:30071. pubmed.ncbi.nlm.nih.gov/39963574
  7. Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. International Journal of Cosmetic Science. 2009;31(5):327-345. pubmed.ncbi.nlm.nih.gov/19570099
  8. Aruan RR, Hutabarat H, Widodo AA, et al. Double-blind, randomized trial on the effectiveness of acetylhexapeptide-3 cream and palmitoyl pentapeptide-4 cream for crow's feet. Journal of Clinical and Aesthetic Dermatology. 2023;16(2):37-43. pubmed.ncbi.nlm.nih.gov/36909866
  9. Bjerke DL, Li J, Gao Y, et al. A framework for the safety evaluation of peptides in cosmetics. Current Research in Toxicology. 2026;10:100291. pubmed.ncbi.nlm.nih.gov/41953401

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.